Teaching Old Drugs New Tricks | May 7, 2012 Issue - Vol. 90 Issue 19 | Chemical & Engineering News
Volume 90 Issue 19 | p. 6 | News of The Week
Issue Date: May 7, 2012

Teaching Old Drugs New Tricks

Research: NIH program aims to find new uses for promising compounds shelved by pharma
Department: Government & Policy
News Channels: Biological SCENE
Keywords: NIH, NCAST, Drug development, Pfizer, Astrazentica, Eli Lilly & Co.
[+]Enlarge
Collins
Credit: NIH
Collins
 
Collins
Credit: NIH
[+]Enlarge
Sebelius
Credit: HHS
Sebelius
 
Sebelius
Credit: HHS

Under a pilot program announced by NIH last week, dozens of drug compounds that have advanced to clinical studies but are no longer being pursued for their original indication will be available to NIH-funded researchers. The program provides research grant support and template agreements with the pharmaceutical firms that own the compounds.

The pilot program—Discovering New Therapeutic Uses for Existing Molecules—is the first major endeavor of the National Center for Advancing Translational Sciences (NCATS), which was established this year with a budget of $575 million. The collaborative program initially involves three pharmaceutical partners—Pfizer, AstraZeneca, and Eli Lilly & Co.—which have agreed to make 24 compounds available.

“To accelerate our nation’s therapeutic development process, it is essential that we forge strong, innovative, and strategic partnerships across government, academia, and industry,” Department of Health & Human Services Secretary Kathleen Sebelius said at the May 3 rollout of the program. She added that this pilot is effectively the “crowdsourcing” of pharma compounds to the brightest drug development minds in the country.

The compounds from the pharmaceutical partners are about halfway through the development pipeline, having been studied for five to seven years with tens of millions of dollars invested in them. They have cleared the safe-for-human-use step.

Interested researchers can begin applying for NCATS grants beginning next month. The applications will be peer reviewed. NCATS will dedicate $20 million to the program in fiscal 2013 to fund awards.

NIH and NCATS are playing a matchmaking role in this process, explained NIH Director Francis S. Collins at the rollout. The goal is to create new opportunities for drugs that failed their intended use, a redirection that’s happened serendipitously. “We must generate more success stories in a systematic way,” he said.

For their part, the drug firms have committed to supply researchers with the compounds and related data.

“Pfizer has a rich history of partnering with the academic and public sectors to discover and develop innovative medicines,” said Rod MacKenzie, head of Pfizer PharmaTherapeutics R&D. “We believe that participating in this unique program, and making well-researched molecules available to NIH’s broad network of researchers, is another important step in advancing a vibrant biomedical ecosystem.”

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Comments
Abraham Nudelman (May 7, 2012 4:43 AM)
Would it be possible to obtain the formulae of the compounds, as well as the indication for which they were tested originally?
Thank you

Sincerely yours,
Abraham Nudelman

Professor of Medicinal Chemistry
Division of Medicinal Chemistry
Chemistry Department
Bar Ilan University
Ramat Gan, 52900, ISRAEL
Phone/FAx - 972-3-531-8314


Leave A Comment

*Required to comment